Cargando…

Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization

Hepatocellular carcinoma (HCC) is a common cause of cancer-related death, with incidence increasing worldwide. Unfortunately, the overall prognosis for patients with HCC is poor and many patients present with advanced stages of disease that preclude curative therapies. Diagnostic and interventional...

Descripción completa

Detalles Bibliográficos
Autores principales: Vande Lune, Patrick, Abdel Aal, Ahmed K., Klimkowski, Sergio, Zarzour, Jessica G., Gunn, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018317/
https://www.ncbi.nlm.nih.gov/pubmed/29951363
http://dx.doi.org/10.14218/JCTH.2017.00045
_version_ 1783334931385024512
author Vande Lune, Patrick
Abdel Aal, Ahmed K.
Klimkowski, Sergio
Zarzour, Jessica G.
Gunn, Andrew J.
author_facet Vande Lune, Patrick
Abdel Aal, Ahmed K.
Klimkowski, Sergio
Zarzour, Jessica G.
Gunn, Andrew J.
author_sort Vande Lune, Patrick
collection PubMed
description Hepatocellular carcinoma (HCC) is a common cause of cancer-related death, with incidence increasing worldwide. Unfortunately, the overall prognosis for patients with HCC is poor and many patients present with advanced stages of disease that preclude curative therapies. Diagnostic and interventional radiologists play a key role in the management of patients with HCC. Diagnostic radiologists can use contrast-enhanced computed tomography (CT), magnetic resonance imaging, and ultrasound to diagnose and stage HCC, without the need for pathologic confirmation, by following established criteria. Once staged, the interventional radiologist can treat the appropriate patients with percutaneous ablation, transarterial chemoembolization, or radioembolization. Follow-up imaging after these liver-directed therapies for HCC can be characterized according to various radiologic response criteria; although, enhancement-based criteria, such as European Association for the Study of the Liver and modified Response Evaluation Criteria in Solid Tumors, are more reflective of treatment effect in HCC. Newer imaging technologies like volumetric analysis, dual-energy CT, cone beam CT and perfusion CT may provide additional benefits for patients with HCC.
format Online
Article
Text
id pubmed-6018317
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-60183172018-06-27 Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization Vande Lune, Patrick Abdel Aal, Ahmed K. Klimkowski, Sergio Zarzour, Jessica G. Gunn, Andrew J. J Clin Transl Hepatol Review Article Hepatocellular carcinoma (HCC) is a common cause of cancer-related death, with incidence increasing worldwide. Unfortunately, the overall prognosis for patients with HCC is poor and many patients present with advanced stages of disease that preclude curative therapies. Diagnostic and interventional radiologists play a key role in the management of patients with HCC. Diagnostic radiologists can use contrast-enhanced computed tomography (CT), magnetic resonance imaging, and ultrasound to diagnose and stage HCC, without the need for pathologic confirmation, by following established criteria. Once staged, the interventional radiologist can treat the appropriate patients with percutaneous ablation, transarterial chemoembolization, or radioembolization. Follow-up imaging after these liver-directed therapies for HCC can be characterized according to various radiologic response criteria; although, enhancement-based criteria, such as European Association for the Study of the Liver and modified Response Evaluation Criteria in Solid Tumors, are more reflective of treatment effect in HCC. Newer imaging technologies like volumetric analysis, dual-energy CT, cone beam CT and perfusion CT may provide additional benefits for patients with HCC. XIA & HE Publishing Inc. 2018-01-05 2018-06-28 /pmc/articles/PMC6018317/ /pubmed/29951363 http://dx.doi.org/10.14218/JCTH.2017.00045 Text en © 2018 Authors. http://creativecommons.org/licenses/by-nc/4.0/ This article has been published under the terms of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. “This article has been published in Journal of Clinical and Translational Hepatology at DOI: 10.14218/JCTH.2017.00045 and can also be viewed on the Journal’s website at http://www.jcthnet.com”.
spellingShingle Review Article
Vande Lune, Patrick
Abdel Aal, Ahmed K.
Klimkowski, Sergio
Zarzour, Jessica G.
Gunn, Andrew J.
Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
title Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
title_full Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
title_fullStr Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
title_full_unstemmed Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
title_short Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization
title_sort hepatocellular carcinoma: diagnosis, treatment algorithms, and imaging appearance after transarterial chemoembolization
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018317/
https://www.ncbi.nlm.nih.gov/pubmed/29951363
http://dx.doi.org/10.14218/JCTH.2017.00045
work_keys_str_mv AT vandelunepatrick hepatocellularcarcinomadiagnosistreatmentalgorithmsandimagingappearanceaftertransarterialchemoembolization
AT abdelaalahmedk hepatocellularcarcinomadiagnosistreatmentalgorithmsandimagingappearanceaftertransarterialchemoembolization
AT klimkowskisergio hepatocellularcarcinomadiagnosistreatmentalgorithmsandimagingappearanceaftertransarterialchemoembolization
AT zarzourjessicag hepatocellularcarcinomadiagnosistreatmentalgorithmsandimagingappearanceaftertransarterialchemoembolization
AT gunnandrewj hepatocellularcarcinomadiagnosistreatmentalgorithmsandimagingappearanceaftertransarterialchemoembolization